Table 3. Multivariate analysis for overall survival according to the expression of FGFR4-related genes.
Variables | Hazard ratio (95% CI) | p-value |
---|---|---|
FGF19 | ||
FGF19 (high vs. low) | 0.38 (0.18–0.81) | 0.012 |
Sex (male vs. female) | 1.36 (0.52–3.55) | 0.53 |
Age (≥ 60 years vs. < 60 years) | 0.76 (0.34–1.69) | 0.50 |
N stage (N1 vs. N0 or Nx) | 1.44 (0.68–3.01) | 0.35 |
Differentiation (poor vs. well or moderate) | 0.24 (0.07–0.86) | 0.029 |
FGF21 | ||
FGF21 (high vs. low) | 0.41 (0.19–0.89) | 0.024 |
Sex (male vs. female) | 1.16 (0.44–3.03) | 0.76 |
Age (≥ 60 years vs. < 60 years) | 0.73 (0.33–1.60) | 0.43 |
N stage (N1 vs. N0 or Nx) | 1.84 (0.85–3.99) | 0.13 |
Differentiation (poor vs. well or moderate) | 0.30 (0.08–1.08) | 0.065 |
FGFR4 | ||
FGFR4 (high vs. low) | 0.32 (0.14–0.72) | 0.006 |
Sex (male vs. female) | 1.12 (0.41–3.01) | 0.83 |
Age (≥ 60 years vs. < 60 years) | 0.95 (0.44–2.16) | 0.95 |
N stage (N1 vs. N0 or Nx) | 1.90 (0.87–4.16) | 0.11 |
Differentiation (poor vs. well or moderate) | 0.30 (0.08–1.10) | 0.069 |
KLB | ||
KLB (high vs. low) | 0.47 (0.20–1.01) | 0.077 |
Sex (male vs. female) | 1.11 (0.42–2.94) | 0.84 |
Age (≥ 60 years vs. < 60 years) | 0.81 (0.37–1.80) | 0.61 |
N stage (N1 vs. N0 or Nx) | 1.83 (0.83–4.05) | 0.14 |
Differentiation (poor vs. well or moderate) | 0.40 (0.11–1.46) | 0.17 |
Abbreviations: CI = confidence interval.